Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02767414
Other study ID # RESP16001
Secondary ID
Status Completed
Phase N/A
First received May 6, 2016
Last updated December 4, 2016
Start date July 2016
Est. completion date October 2016

Study information

Verified date December 2016
Source Ellume Pty Ltd
Contact n/a
Is FDA regulated No
Health authority Australia: Department of Health and Ageing Therapeutic Goods Administration
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to validate the sensitivity and specificity of the Respirio Flu Test and the eLab Flu Test in detecting Influenza A as compared to the gold standard for detection, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR).

The secondary aims are to:

Validate the sensitivity and specificity of the Respirio Flu Test and the eLab Flu Test in detecting Influenza B as compared to the gold standard for detection, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR); Evaluate the correct interpretation of the Respirio Flu Test by subjects with influenza-like symptoms; Evaluate the subjects' satisfaction with the convenience, comfort and ease of use of the Respirio Flu Test.


Recruitment information / eligibility

Status Completed
Enrollment 1500
Est. completion date October 2016
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender Both
Age group 1 Year and older
Eligibility Inclusion Criteria:

- Male and female subjects aged = 1 year;

- Rhinorrhea;

- = 5 days from onset of influenza-like illness symptoms;

- Subject (or parent/legal guardian) capable and willing to give informed consent/assent;

- Subject (or parent/legal guardian) able to read and write English.

Exclusion Criteria:

- Has undergone treatment with antivirals within the previous 7 days;

- Has been vaccinated by means of an influenza nasal spray/mist vaccine within the previous 7 days;

- Recent craniofacial injury or surgery, including surgery to correct deviation of the nasal septum, within the previous 6 months;

- Currently enrolled in another clinical trial or used any investigational device within 90 days preceding informed consent;

- Has had prior exposure to the Respirio Flu Test or eLab Flu Test.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Device:
Respirio Flu Test
The Respirio Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
eLab Flu Test
The eLab Flu Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasopharyngeal swab samples. The eLab Flu Test generates a result within 10 minutes.
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.

Locations

Country Name City State
Australia Doctors@Carindale Brisbane Queensland
Australia Mater Hospital - Brisbane Brisbane Queensland
Australia Red Hill Doctors Surgery Brisbane Queensland
Australia Barwon Health - Geelong Geelong Victoria
Australia The Royal Children's Hospital Melbourne Victoria
Australia Capalaba Medical Centre Redland Queensland
Australia Clinical Trials Centre - University of the Sunshine Coast Sippy Downs Queensland

Sponsors (1)

Lead Sponsor Collaborator
Ellume Pty Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Of participants positive for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza A by Respirio Flu Test. Establish sensitivity against a gold standard. Report as a percentage of participants with 96% confidence limits. Day 1 No
Primary Of participants positive for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza A by eLab Flu Test. Establish sensitivity against a gold standard. Report as a percentage of participants with 96% confidence limits. Day 1 No
Primary Of participants negative for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza A by Respirio Flu Test. Establish specificity against a gold standard. Report as a percentage of participants with 96% confidence limits. Day 1 No
Primary Of participants negative for influenza A by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza A by eLab Flu Test. Establish specificity against a gold standard. Report as a percentage of participants with 96% confidence limits. Day 1 No
Secondary Of participants positive for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza B by Respirio Flu Test. Establish sensitivity against a gold standard. Report as a percentage of participants with 96% confidence limits. Day 1 No
Secondary Of participants positive for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are positive for influenza B by eLab Flu Test. Establish sensitivity against a gold standard. Report as a percentage of participants with 96% confidence limits. Day 1 No
Secondary Of participants negative for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza B by Respirio Flu Test. Establish specificity against a gold standard. Report as a percentage of participants with 96% confidence limits. Day 1 No
Secondary Of participants negative for influenza B by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR), the percentage who are negative for influenza B by eLab Flu Test. Establish specificity against a gold standard. Report as a percentage of participants with 96% confidence limits. Day 1 No
Secondary Percent of participants who correctly interpret result of Respirio Flu Test. Agreement between trained staff and participants. Report as a percentage of participants with 95% confidence limits. Day 1 No
Secondary Scores from questionnaire to assess ease of use, comfort and convenience of Respirio Flu Test. The ease of use questionnaire will provide total number of responses to each question and the percentage of participants selecting each response (on a 5 point Likert scale). Day 1 No
See also
  Status Clinical Trial Phase
Completed NCT03999554 - Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines Phase 1
Completed NCT06385821 - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus Phase 3
Completed NCT02487173 - Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B N/A
Completed NCT01701752 - Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults Phase 1
Enrolling by invitation NCT03207152 - Biomarkers Predicting Infectivity in an Experimental Human Influenza Model Phase 1
Terminated NCT05567783 - A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A Phase 2
Not yet recruiting NCT00987012 - The Influence of Fortified Pomegranate Juice (Punica Granatum) on Seasonal Influenza and Swine Flu Patients N/A
Not yet recruiting NCT05928507 - FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol
Completed NCT03651544 - The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac Phase 1
Completed NCT02623322 - A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults Phase 2
Completed NCT03196661 - Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population Phase 1
Recruiting NCT06160531 - Influenza Viral Challenge Study of CC-42344 in Healthy Participants Phase 2
Recruiting NCT06191393 - SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings N/A
Completed NCT06127108 - Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel N/A
Completed NCT05163730 - Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel N/A
Not yet recruiting NCT06392451 - LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia N/A
Recruiting NCT04896853 - Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® Phase 1
Not yet recruiting NCT05787444 - Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
Completed NCT05354115 - Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel. N/A
Completed NCT02014870 - Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers Phase 1